How Amgen Inc. Makes Money

Amgen's business model is built on one of the most capital-intensive and intellectually demanding processes in American enterprise: translating fundamental biological discoveries into regulated, manufactured medicines that can be sold at scale. Unlike traditional pharmaceutical companies that synthesize small-molecule drugs through chemical processes, Amgen produces large-molecule biologic drugs — complex proteins engineered inside living cell systems, then purified, formulated, and delivered to patients. This distinction matters enormously from a commercial standpoint. Biologics are extraordinarily difficult and expensive to replicate, which historically gave Amgen near-impenetrable market positions for its flagship products. They also require massive, precision-engineered manufacturing infrastructure — the kind of capital moat that a startup competitor simply cannot build in five years regardless of how much venture funding it raises. Amgen generates revenue through four primary mechanisms: branded biologic product sales in the United States, international product sales in Europe and other markets, licensing and royalty income from partnerships, and a rapidly expanding biosimilars portfolio. In fiscal year 2024, total revenues reached approximately $33.4 billion, with product sales accounting for the overwhelming majority. The company's largest revenue contributors that year included Repatha (evolocumab), the PCSK9-inhibitor cholesterol drug that generated approximately $2.1 billion; Prolia (denosumab) for osteoporosis at approximately $2.7 billion; XGEVA (denosumab) for bone metastases at approximately $2.1 billion; Enbrel (etanercept) for rheumatoid arthritis generating approximately $3.6 billion domestically; and Otezla (apremilast) for psoriasis contributing approximately $2.2 billion. Tepezza, acquired through the Horizon Therapeutics deal, generated approximately $1.9 billion in 2024, while Krystexxa contributed approximately $800 million. The business model's profitability depends on a high-margin, volume-driven commercial infrastructure. Amgen employs thousands of pharmaceutical sales representatives and managed care specialists who work directly with hospital systems, pharmacy benefit managers, specialty pharmacies, and healthcare providers to ensure formulary placement and reimbursement coverage. Unlike consumer goods companies that sell to millions of individual buyers, Amgen's commercial model requires navigating a concentrated set of institutional purchasers — three major pharmacy benefit managers (Express Scripts, CVS Caremark, and OptumRx) collectively control the drug coverage decisions for the majority of commercially insured Americans. Securing favorable formulary tiers with these intermediaries is as important to Amgen's revenue as scientific innovation itself. Research and development spending is the engine of Amgen's future revenue. The company invested approximately $4.8 billion in R&D during fiscal year 2024, representing roughly 14% of total revenues. This spending funds a pipeline spanning oncology, cardiometabolic diseases, inflammation, rare diseases, and neuroscience. Key pipeline assets include MariTide (maridebart cafraglutide), an investigational obesity and diabetes drug that targets both GLP-1 receptor agonism and GIP receptor antagonism — a mechanism that could position Amgen to compete directly with Eli Lilly's tirzepatide and Novo Nordisk's semaglutide in the exploding weight loss drug market. The company has also advanced AMG 133 through Phase 2 trials with weight loss data that attracted significant investor attention in 2024 and 2025. Biosimilars represent Amgen's most structurally interesting strategic bet. The company entered this segment by applying its own biologic manufacturing expertise to produce lower-cost versions of rival companies' off-patent biologics. Amgen's biosimilar portfolio includes Mvasi (biosimilar bevacizumab, competing with Genentech's Avastin), Kanjinti (biosimilar trastuzumab, competing with Genentech's Herceptin), Riabni (biosimilar rituximab), Amjevita (biosimilar adalimumab, competing with AbbVie's Humira), Blincyto biosimilar, and others. The biosimilars business generated approximately $1.6 billion in revenue in 2024, up significantly from prior years as Humira biosimilars gained market traction following AbbVie's loss of U.S. Exclusivity in January 2023. This segment has lower margins than branded biologics but provides volume growth and demonstrates Amgen's commitment to lower-cost medicine access — a narrative that carries important political value during a period of intense congressional scrutiny of drug pricing. Amgen's manufacturing business model is itself a competitive asset. The company operates large-scale biologics manufacturing facilities in Thousand Oaks, Puerto Rico, Rhode Island, and internationally in the Netherlands and Singapore. These facilities produce drug substance and finished drug product under FDA and EMA Good Manufacturing Practice requirements. The capital investment required to build and validate these facilities — routinely running into hundreds of millions or billions of dollars per site — creates a structural barrier that reinforces Amgen's competitive position. The company has invested in next-generation multiproduct manufacturing facilities that can be adapted to different biologic drug types with shorter reconfiguration times, improving capital efficiency. The financial model generates enormous free cash flow. Amgen's operating margins have typically run between 30% and 35% on a GAAP basis and higher on an adjusted basis, reflecting both the pricing power of its branded biologics and decades of operational refinement. In fiscal year 2024, the company reported non-GAAP operating income of approximately $13.5 billion. Capital allocation historically favored a combination of R&D reinvestment, dividend payments (the quarterly dividend reached $2.25 per share in 2024, yielding approximately 3%), and share repurchases. However, the $27.8 billion Horizon acquisition significantly elevated Amgen's debt load — long-term debt reached approximately $58 billion following the deal's closing — shifting near-term capital allocation priorities toward debt reduction while maintaining the dividend. Geographic diversification is increasingly important to Amgen's model. While the United States accounted for approximately 75% of product revenues in 2024, the company has been growing its ex-U.S. Presence, particularly in Europe where biosimilars face more receptive regulatory and market environments than in the U.S. Amgen's European commercial infrastructure, bolstered by its 2013 acquisition of deCODE Genetics in Iceland and longstanding partnerships across major EU markets, provides both revenue diversification and access to genomic research populations that inform drug discovery.

Amgen's growth strategy rests on four interdependent pillars that CEO Robert Bradway has consistently articulated to investors since 2020. The first pillar is maximizing the commercial performance of the Horizon portfolio, particularly Tepezza in thyroid eye disease and Krystexxa in refractory gout. Tepezza has significant underpenetrated market opportunity — the vast majority of thyroid eye disease patients remain undertreated despite Tepezza's strong clinical evidence — and Amgen has invested heavily in patient identification programs, specialist education, and payer coverage expansion since the acquisition closed. The second pillar is advancing the next generation of innovative biologics, led by MariTide in obesity, tarlatamab in oncology, and olpasiran in cardiovascular disease. Olpasiran, a small interfering RNA drug targeting lipoprotein(a), completed a positive Phase 2 trial and is moving toward Phase 3, addressing an unmet need in a population that statins and PCSK9 inhibitors do not adequately treat. The third pillar is building the biosimilars business into a durable revenue contributor. Amgen has committed to launching biosimilar versions of multiple high-revenue biologics as they lose exclusivity through 2030, leveraging its manufacturing capabilities to achieve cost structures that enable profitable competition at biosimilar price points. The fourth pillar is disciplined financial management — specifically debt reduction from the Horizon acquisition while preserving R&D investment and the dividend. Management has targeted returning to investment-grade credit metrics by 2027, which would restore full capital allocation flexibility including potential smaller bolt-on acquisitions in therapeutic categories where Amgen wants to build pipeline depth. The geographic growth opportunity in emerging markets, particularly China and Japan, where Amgen is building direct commercial presence, represents a longer-term revenue diversification vector.